Denosumab alleviates intervertebral disc degeneration adjacent to lumbar fusion by inhibiting endplate osteochondral remodeling and vertebral osteoporosis in ovariectomized rats

BACKGROUND: Although adjacent segmental intervertebral disc degeneration (ASDD) is one of the most common complications after lumbar fusion, its exact mechanism remains unclear. As an antibody to RANKL, denosumab (Dmab) effectively reduces bone resorption and stimulates bone formation, which can inc...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Qi, Tian, Fa-Ming, Liu, Fang, Fang, Jia-Kang, Hu, Yun-Peng, Lian, Qiang-Qiang, Zhou, Zhuang, Zhang, Liu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161944/
https://www.ncbi.nlm.nih.gov/pubmed/34049577
http://dx.doi.org/10.1186/s13075-021-02525-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161944/
https://www.ncbi.nlm.nih.gov/pubmed/34049577
http://dx.doi.org/10.1186/s13075-021-02525-8

Ejemplares similares